OECD Home › Science and technology › Publications & Documents › Best Practices / Guidelines
Best Practices / Guidelines
The ability to effectively use these vast amounts of knowledge will depend in part on the bringing together of different strands of information, data and biological materials within human biobanks and genetic research databases (HBGRDs).
OECD’s Working Party on Manufactured Nanomaterials (WPMN) launched a Sponsorship Programme in November 2007. The programme involves OECD member countries, as well as some non-member economies and other stakeholders to pool expertise and to fund the safety testing of specific Manufactured Nanomaterials (MNs). In launching this Sponsorship Programme, the WPMN agreed on a priority list of 13 MNs for testing (based on materials which are
Genetics is playing an increasingly important role in health care. New technical advances and information deriving from human genome research are changing health care practices and the economics of healthcare provision.
This report presents the outcome of discussions held by the OECD member countries, together with a number of key partner countries, under the auspices of an expert Task Force established by the OECD Working Party on Biotechnology.
These recommendations are intended to assist all actors involved when trying to improve the international sharing of, and access to, research data.
These guidelines offer principles and best practices for the licensing of genetic inventions used for the purpose of human health care.
English, , 365kb
This guidance provides the basis for best practice in the management of biological resource centres and all laboratories maintaining replicable biological materials.
English, , 260kb
This document provides a framework for the national certification (independent review by third party) of biological resource centres as defined by the OECD. Compliance with this guidance is mandatory for those bodies that are part of a Global Biological Resource Centre Network.
Biological Resource Centres (BRCs) are considered to be one of the key elements for sustainable international scientific infrastructure, which is necessary to underpin successful delivery of the benefits of biotechnology.